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Introduction {#s1}
============

The leading cause of mortality worldwide, coronary artery disease is on the rise owing to higher sanitary levels, urbanization, and aging populations.^[@R1]-[@R3]^ Coronary artery disease is responsible for 6.4 deaths per 10000 Iranian population, and 35% of all mortalities are due to cardiac diseases.^[@R4],[@R5]^ Coronary artery bypass grafting and percutaneous coronary interventions (PCI) are the principal revascularization approaches.^[@R6]-[@R8]^ Early PCI is the method of choice for myocardial infarction with ST elevation, and a shorter interval between event and hospital arrival can result in lower mortality rates.^[@R7]-[@R9]^

Coronary angiography is the most common heart procedure worldwide, and contrast-induced nephropathy (CIN) has shown increased rates in those undergoing this modality. CIN is commonly observed among patients undergoing primary PCI, even in those with a normal renal function.^[@R10]^ Chronic kidney alterations may affect those with previous renal insufficiency up to 12%; however, the symptoms are seen in less than 1%. CIN is an acute decreased renal function after an intravenous infusion of iodine contrast media, which is the third cause of hospital-acquired acute renal failure and is due to cardiac procedures in half of the cases.^[@R11]-[@R13]^ Furthermore, it may increase the risk of hemodialysis and death.^[@R10]^

CIN may be secondary to direct tubular toxicity, vasoconstriction, and oxidative stress.^[@R14]-[@R16]^ Statins (HMG-CoA reductase inhibitor) may lessen atherosclerosis, inflammation, endothelial dysfunction, and platelet hyperactivity.^[@R15]^ Good effects of statins such as atorvastatin and rosuvastatin on oxidative stress, nitric oxide synthesis, and endothelial function constitute some of the mechanisms responsible for the renoprotective effects in those with chronic kidney disease.^[@R14]^ Nevertheless, not only is there controversy surrounding the efficacy of statins for the prevention of CIN, but also there have been reports on varying efficacies of various statins.^[@R15]-[@R21]^ Accordingly, in this study the efficacy of atorvastatin and rosuvastatin for the prevention of CIN was assessed among patients undergoing primary PCI.

Materials and Methods {#s2}
=====================

This single-blind randomized clinical trial was performed on 302 random patients with myocardial infarction with ST-segment elevation undergoing primary PCI in a training referral hospital in 2015. The patients with known hypersensitivity to statins, those with cardiogenic shock status, pregnant and lactating females, and those who had received a contrast agent within the preceding week were excluded from the study.

The patients were randomly assigned to receive either atorvastatin (n = 150) or rosuvastatin (n = 152). Unfortunately, 7 patients died before 48 hours from presentation. Thus, 144 patients in atorvastatin group and 151 patients in rosuvastatin were evaluated.

Atorvastatin dose was 80 mg at admission and daily up to 48 hours later, and rosuvastatin dose was 40 mg at admission and daily up to 48 hours after the procedure. Before the PCI procedure, hemoglobin, lipid profile, baseline blood urea nitrogen (BUN), creatinine, and glomerular filtration rate (GFR) were assessed. The Mehran CIN-Risk score was calculated based on Mehran et al study.^[@R22]^ Thereafter, BUN, creatinine, and GFR were assessed for 48 hours.

The prediction of creatinine clearance (in mL/min) by the Cockcroft-Gault formula was calculated as (140 − age) × body weight/serum creatinine × 72 (× 0.85 if female).^[@R23]^ Based on previous study, CIN was defined as grade 0 (serum creatinine increase \<25% above baseline and \<0.5 mg/dL above baseline), grade 1 (serum creatinine increase ≥25% above baseline and \<0.5 mg/dL above baseline), or grade 2 (serum creatinine increase ≥0.5 mg/dL above baseline).^[@R18]^

Statistical Analysis {#s2-1}
--------------------

The continuous variables are expressed as mean ± standard deviation, and they were compared using the Student t-test or the Mann-Whitney U-test, as appropriate. The categorical variables are expressed as frequencies and percentages, and they were compared between the aforementioned groups applying the χ2 test or the Fisher exact test. All *P* values \<0.05 were considered statistically significant. All the data analyses were conducted using SPSS (version 19.0) (Chicago, Illinois, US).

Results {#s3}
=======

A total of 295 patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI were enrolled in the study. The patients were randomized to 80 mg atorvastatin (n = 144) or 40 mg rosuvastatin (n = 151), respectively, prior to primary PCI. The baseline characteristics were not difference between 2 groups ([Table 1](#T1){ref-type="table"}). Also, Mehran's CIN risk score was not different between statin groups.

###### Baseline characteristics of the 2 study groups

  ----------------------------------------------------------- ---------------------------- ------------------- -------
  **Variables**                                               **Drugs**                    ***P*** **value**   
  **Rosuvastatin (n = 151)**                                  **Atorvastatin (n = 144)**                       
  Age \> 75 years old, No. (%)                                15(9.9%)                     8(5.6%)             0.161
  Male gender, No. (%)                                        130(86.1%)                   118(81.9%)          0.330
  Cigarette smoking, No. (%)                                  65(43.0%)                    75(52.1%)           0.120
  Diabetes mellitus, No. (%)                                  42(27.8%)                    38(26.4%)           0.783
  Hypertension, No. (%)                                       60(39.7%)                    72(50.0%)           0.076
  Hypercholesterolemia, No. (%)                               8(5.3%)                      14(9.7%)            0.148
  Prior CABG, No. (%)                                         13(8.6%)                     7(4.9%)             0.201
  Prior PCI, No. (%)                                          25(16.6%)                    18(12.5%)           0.324
  Total cholesterol                                           166.4 ± 42.4                 168.8 ± 42.0        0.638
  Low-density lipoprotein                                     104.2 ± 76.2                 102.0 ± 33.6        0.372
  High-density lipoprotein                                    42.4 ± 8.9                   40.7 ± 7.9          0.117
  Triglycerides                                               123.6 ± 56.7                 136.2 ± 77.0        0.342
  Hemoglobin                                                  14.5 ± 1.6                   14.4 ± 1.5          0.567
  Angiotensin-converting enzyme-inhibitor, No. (%)            103 (68.2%)                  94 (65.3%)          0.593
  Angiotensin II receptor blocker use, No. (%)                27 (17.9%)                   33 (22.9%)          0.283
  Beta-blocker use, No. (%)                                   118 (78.1%)                  115 (79.9%)         0.718
  Diuretic use, No. (%)                                       55 (36.4%)                   50 (34.7%)          0.760
  Calcium channel blocker, No. (%)                            11 (7.3%)                    11 (7.6%)           0.908
  Angiography data, No. (%)                                                                                    
  Multi-vessel                                                85 (56.3%)                   81 (56.3%)          0.994
  Single-vessel                                               65 (43.0%)                   61(42.4%)           0.905
  Ejection fraction \< 30%                                    36 (23.8%)                   31(21.5%)           0.635
  Mehran's contrast-induced nephropathy risk score, No. (%)                                                    
  ≤5                                                          57 (37.7%)                   58(40.3%)           0.966
  6--10                                                       67 (44.4%)                   62(43.1%)           
  11--16                                                      23 (15.2%)                   21(14.6%)           
  ≥ 16                                                        4 (2.6%)                     3(2.1%)             
  ----------------------------------------------------------- ---------------------------- ------------------- -------

Totally, 36 patients (12.2%) had eGFR lower than 60 mL/min/1.73 m^2^; which was not different between groups (*P* value: 0.36). After 48 hours from primary PCI, the CIN were observed in 63 patients (21.4%). Of those, 17% (n = 50) were grade 1 CIN, while 4.4% (n = 13) were grade 2 CIN. There was no significant between statin groups regarding the CIN grading (*P* value: 0.14) ([Table 2](#T2){ref-type="table"}; [Figure 1](#F1){ref-type="fig"}).

###### Baseline and 48 hour laboratory data and frequency of CIN between groups

  --------------------------------------------------- -------------------------- -------------------------- -------------------
                                                      **Rosuvastatin (n=151)**   **Atorvastatin (n=144)**   ***P*** **value**

  Baseline creatinine (mg/dL)                         1.02±0.41                  0.93±0.42                  \<0.001

  Baseline BUN (mg/dL)                                18.5±8.02                  16.9±8.3                   0.002

  Baseline eGFR (mL/min/1.73 m^2^)                    94.06±33.1                 107±39.01                  0.002

  Baseline eGFR \<60 mL/min/1.73 m^2^, No. (%)        21 (13.9)                  15 (10.4)                  0.362

  48 hours creatinine (mg/dL)                         1.08±0.54                  1.03±0.57                  0.009

  48 hours BUN (mg/dL)                                21.2±10.5                  20.4±13.1                  0.028

  48 hours eGFR (ml/min/1.73 m^2^)                    90.2±33.6                  98.9±40.0                  0.053

  Creatinine, ∆ (from baseline to 48 hours) (mg/dL)   0.07±0.28                  0.11±0.34                  0.300

  Contrast induced nephropathy, No. (%)                                                                     

  Grade 0                                             125 (19.4)                 107 (74.3)                 \
                                                                                                            0.144

  Grade 1                                             22 (14.6)                  28 (19.4)                  

  Grade 2                                             4 (2.6)                    9 (6.3)                    
  --------------------------------------------------- -------------------------- -------------------------- -------------------
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Discussion {#s4}
==========

The present study revealed that high doses rosuvastatin in setting of STEMI patients who underwent primary PCI on preventing CIN is effective compared with high dose atorvastatin. Muñoz et al^[@R17]^ compared the efficacy of simvastatin and pravastatin for CIN prophylaxis among 261 patients and reported rates of 17.9% and 8.6% in the simvastatin and pravastatin groups, respectively, with the difference constituting statistical significance. There was no dialysis-requiring case in their study, similar to our study. However, the authors found that 14.5% and 6.9% of their patients in the simvastatin and pravastatin groups, correspondingly, had acute renal failure - with a significant difference. Totally, they concluded that pravastatin had better efficacy for CIN prophylaxis.

Leoncini et al^[@R16]^ had 2 groups of patients with and without rosuvastatin and reported that 15.1% and 6.7% had CIN in the control and drugs groups, respectively, showing a statistically significant difference. In addition, their rosuvastatin group experienced lower death and re-infarction rates.

Toso et al^[@R19]^ compared 2 groups of patients with and without atorvastatin and reported that 11% in the control group and 10% in the drugs group had CIN, showing no statistically significant difference. The investigators concluded that atorvastatin had no effect on CIN prevention. Pappy et al^[@R20]^ revealed in their meta-analysis that statins were effective drugs for CIN prophylaxis, which is concordant with our results. The results of our study are reliable because of the use of group matching and reduction of the effects of confounding factors.

Kaya and colleagues^[@R18]^ for the first time compared high dose atorvastatin and rosuvastatin for CIN prophylaxis among 192 patients with STEMI under primary PCI and reported that totally 8.9% had CIN without significant difference. They showed that the grade 1 CIN occurred in 9.2% and 5.3% of patients treated with atorvastatin and rosuvastatin groups, while the rates for grade 2 CIN occurred 1% and 2.1%, respectively (*P* value: 0.50). Compared with our study, presence of CIN was more in our observation (12.2%); however, same as Kaya and colleagues^[@R18]^ there was no significant difference were observed between groups in our study.

Totally, according to the obtained results, it may be concluded that atorvastatin and rosuvastatin have similar efficacy for preventing CIN. However, further studies with larger sample sizes and multi-center samplings are required to attain more definite results.

Ethical approval {#s5}
================

Informed consent was received from all the patients, and the Helsinki Declaration was observed throughout the study. The local ethics committee of the center approved this study.

Competing interests {#s6}
===================

None.
